| CRL |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$2.78 vs. cons $2.75 |
MEDIUM |
| CRL |
Report |
Total revenue |
IN-LINE |
pred ~$987M vs. cons $979.9M |
MEDIUM |
| CRL |
Report |
DSA revenue |
IN-LINE |
pred ~$596M vs. cons $592.1M |
MEDIUM |
| CRL |
Guide |
Non-GAAP EPS (FY26) |
UNCHANGED |
guide $10.80-$11.30 vs. cons $11.08 |
MEDIUM |
| CRL |
Guide |
Organic revenue (FY26) |
UNCHANGED |
guide (1.5)%-(0.5)% vs. prior company range (1.5)%-(0.5)% |
MEDIUM |
| CRL |
Guide |
DSA book-to-bill (Q2/H2 commentary) |
BETTER |
guide ~1.02x vs. cons 0.99x |
MEDIUM |
| CRL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| CRL |
Return |
5-day cumulative residual |
-5.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY outlook drives modest H2 revision risk |
LOW |